Launch of generic Farxiga (Dapagliflozin Propanediol tablets)

Released: 01/22/2024

The generic formulation of Farxiga, Dapagilflozin Propanediol tablets has been recently release.

DAPAGLIFLOZIN TABLETS are indicated:

To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.

To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dapagliflozin Propanediol tablets are manufactured by Prasco Laboratories. It is available in 5mg and 10mg tablets.